Hot Features
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1... Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.755 | -15.9156556904 | 17.31 | 18.505 | 14.17 | 9104251 | 15.91379632 | DR |
| 4 | -3.365 | -18.7779017857 | 17.92 | 19.415 | 14.17 | 4990447 | 16.67160129 | DR |
| 12 | -1.415 | -8.86036318096 | 15.97 | 29.23 | 14.17 | 4255241 | 18.62888523 | DR |
| 26 | -3.735 | -20.4209950793 | 18.29 | 29.23 | 13.83 | 3363697 | 17.78744605 | DR |
| 52 | -5.545 | -27.5870646766 | 20.1 | 30.98 | 13.83 | 3502440 | 19.79018139 | DR |
| 156 | 12.785 | 722.316384181 | 1.77 | 36.91 | 1.52 | 3069640 | 16.27282203 | DR |
| 260 | 6.655 | 84.2405063291 | 7.9 | 36.91 | 0.66 | 2624314 | 12.24987453 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.